Avalon GloboCare Corp. is a commercial-stage company focused on developing and delivering precision diagnostic consumer products, advancing cellular therapy intellectual property, and owning commercial real estate properties in the United States. It markets the KetoAir™ breathalyzer, a handheld nanosensor device that measures breath acetone levels to monitor ketosis and fat metabolism, integrated into wellness programs for first responders and ketogenic health management. The company distributes KetoAir™ through wholesale agreements, affiliate programs, and online channels in the United States and United Kingdom, while co-developing additional applications like a cannabis breathalyzer for point-of-care detection. Avalon GloboCare Corp. advances proprietary CAR-T and CAR-NK cell technologies, including bispecific designs and cytokine induction methods protected by patents in multiple jurisdictions. Through subsidiaries like Avalon Quantum AI, LLC and Q&A Distribution, LLC, it operates generative AI software for nutrition and publishing, alongside real estate operations. Founded in 2015 and headquartered in Freehold, New Jersey, Avalon GloboCare Corp. plays a role in the intersection of diagnostics, biotech IP, AI-enabled health tools, and property management within healthcare and real estate markets.